A Study to Evaluate Safety, Tolerability, and Preliminary Effect of the GEN1053 Antibody on Malignant Solid Tumors as Monotherapy
Phase 1/2
Terminated
NCT05435339
| Condition | Solid Tumor, Adult |
|---|
| Phase | Phase 1/2 |
|---|
| Sponsor | Genmab |
|---|
| Status | Terminated |
|---|
| Enrollment | 31 participants |
|---|
| Interventions | GEN1053 |
|---|
| Start date | Oct 4, 2022 |
|---|
| Completion date | May 24, 2024 |
|---|
| Results posted | Apr 22, 2025 |
|---|
Summary
The drug that will be investigated in the study is GEN1053. GEN1053 is an antibody designed to (re)activate and increase antitumor immunity. Since this is the first study of GEN1053 in humans, the main purpose is to evaluate safety. Besides safety, the study will determine the recommended GEN1053 dose to be tested in a larger group of participants and assess preliminary clinical activity of GEN1053. GEN1053 will be studied in a broad group of cancer patients, having different kinds of solid tumors. All participants will get GEN1053. The study consists of two parts: Part 1 tests increasing doses of GEN1053 ("escalation"), followed by Part 2 which tests the recommended phase 2 dose GEN1053 dose from Part 1 ("expansion").
Number of Participants With Dose Limiting Toxicities (DLTs)
Day 1 up to Day 21 · Participants
| GEN1053 Dose Level 1 Q3W | 0 Participants |
|---|
| GEN1053 Dose Level 2 Q3W | 0 Participants |
|---|
| GEN1053 Dose Level 3 Q3W | 0 Participants |
|---|
| GEN1053 Dose Level 4 Q3W | 0 Participants |
|---|
| GEN1053 Dose Level 5 Q3W | 0 Participants |
|---|
| GEN1053 Dose Level 6 Q3W | 0 Participants |
|---|
Number of Participants With At Least One Treatment-emergent Adverse Event (TEAE)
Up to approximately 1.5 years · Participants
| GEN1053 Dose Level 1 Q3W | 1 Participants |
|---|
| GEN1053 Dose Level 2 Q3W | 1 Participants |
|---|
| GEN1053 Dose Level 3 Q3W | 3 Participants |
|---|
| GEN1053 Dose Level 4 Q3W | 1 Participants |
|---|
| GEN1053 Dose Level 5 Q3W | 6 Participants |
|---|
| GEN1053 Dose Level 6 Q3W | 3 Participants |
|---|
Open in BENITIONS
View on ClinicalTrials.gov
All trials
This page summarises publicly available data from ClinicalTrials.gov. It is not medical advice and not investment advice. Always consult a qualified healthcare professional.